Moleculin Biotech (MBRX) Profit After Tax (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Profit After Tax of $15.6 million for Q4 2025, up 334.65% year-over-year from $3.6 million in Q4 2024, and up 161.23% quarter-over-quarter from -$25.4 million in Q3 2025.
Moleculin Biotech (MBRX) Profit After Tax (2016 - 2026) Analysis & Trends
Moleculin Biotech's Profit After Tax history runs 10 years deep, the most recent figure standing at $15.6 million for Q4 2025.
- In Q4 2025, Profit After Tax rose 334.65% year-over-year to $15.6 million; the TTM figure through Dec 2025 stood at -$33.6 million (down 28.7% YoY), while the FY2025 annual figure was -$33.6 million, down 28.68% from the prior year.
- Profit After Tax for Q4 2025 stood at $15.6 million, up from -$25.4 million in the prior quarter.
- The five-year high for Profit After Tax was $15.6 million in Q4 2025, with the low at -$25.4 million in Q3 2025.
- The 5-year median for Profit After Tax is -$6.5 million (2024), against an average of -$6.7 million.
- The sharpest annual moves came in 2021 and 2025: Profit After Tax tumbled 267.66% in 2021, then surged 334.65% in 2025.
- Moleculin Biotech's Profit After Tax stood at -$2.8 million in 2021, then sank by 139.65% to -$6.8 million in 2022, then slumped by 51.68% to -$10.3 million in 2023, then surged by 35.45% to -$6.6 million in 2024, then jumped by 334.65% to $15.6 million in 2025.
- Business Quant data shows MBRX's Profit After Tax at $15.6 million in Q4 2025, -$25.4 million in Q3 2025, and -$17.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | -7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.65 Mn |
| Dec 31, 2025 | 15.56 Mn |
| Sep 30, 2025 | -25.41 Mn |
| Jun 30, 2025 | -17.81 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -6.63 Mn |
| Sep 30, 2024 | -7.01 Mn |
| Jun 30, 2024 | -6.02 Mn |
| Mar 31, 2024 | -6.43 Mn |
| Dec 31, 2023 | -10.27 Mn |
| Sep 30, 2023 | -5.61 Mn |
| Jun 30, 2023 | -5.98 Mn |
| Mar 31, 2023 | -7.92 Mn |
| Dec 31, 2022 | -6.77 Mn |
| Sep 30, 2022 | -8.63 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -6.87 Mn |
| Dec 31, 2021 | -2.83 Mn |
| Sep 30, 2021 | -4.40 Mn |
| Jun 30, 2021 | -4.24 Mn |